Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review.
Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review.
复制标题
代谢作为肺癌的诊断工具的变化：系统评价。
DOI：
10.3390/metabo12060545
复制
发表时间：
2022-06-14
期刊：
影响因子：
4.1
通讯作者：
Mesotten, Liesbet
中科院分区：
文献类型：
--
作者：
Marien, Hanne;Derveaux, Elien;Vanhove, Karolien;Adriaensens, Peter;Thomeer, Michiel;Mesotten, Liesbet
肺癌是全球癌症相关死亡的主要原因，五年生存率从3- 62%不等。筛查的目的是早期发现，但一半的患者被诊断为晚期，限制了治疗的可能性。正电子发射断层扫描-计算机断层扫描（PET-CT）是肺癌检测和分期的基本技术，灵敏度达到96%。然而，由于18 F-氟脱氧葡萄糖（18 F-FDG）摄取升高不是癌症特异性的，PET-CT通常无法区分恶性和非恶性PET阳性高代谢病变，特异性仅为23%。此外，在没有侵入性手术的情况下，肺癌类型之间的区分仍然是不可能的。肺癌的高死亡率和发病率、低生存率以及早期检测、分期和分型的困难促使人们寻找生物标志物来改善诊断过程和预期寿命。代谢组学已经成为解决这些问题的一种有价值的技术。超过150种代谢物与肺癌有关，其中几种在特定代谢物浓度的改变方面的发现是一致的。然而，由于缺乏标准化的患者队列和测量方案，仍然存在更多的变异性而不是一致性。本综述总结了用于早期诊断、分期和分型的代谢生物标志物，并强调了对生物标志物的需求，以预测疾病进展和生存，并支持治疗随访。
Lung cancer is the leading cause of cancer-related mortality worldwide, with five-year survival rates varying from 3–62%. Screening aims at early detection, but half of the patients are diagnosed in advanced stages, limiting therapeutic possibilities. Positron emission tomography-computed tomography (PET-CT) is an essential technique in lung cancer detection and staging, with a sensitivity reaching 96%. However, since elevated 18F-fluorodeoxyglucose (18F-FDG) uptake is not cancer-specific, PET-CT often fails to discriminate between malignant and non-malignant PET-positive hypermetabolic lesions, with a specificity of only 23%. Furthermore, discrimination between lung cancer types is still impossible without invasive procedures. High mortality and morbidity, low survival rates, and difficulties in early detection, staging, and typing of lung cancer motivate the search for biomarkers to improve the diagnostic process and life expectancy. Metabolomics has emerged as a valuable technique for these pitfalls. Over 150 metabolites have been associated with lung cancer, and several are consistent in their findings of alterations in specific metabolite concentrations. However, there is still more variability than consistency due to the lack of standardized patient cohorts and measurement protocols. This review summarizes the identified metabolic biomarkers for early diagnosis, staging, and typing and reinforces the need for biomarkers to predict disease progression and survival and to support treatment follow-up.
登录
查看更多内容
影响因子：
20.8
作者：
Elia I;Haigis MC
通讯作者：
Haigis MC
影响因子：
4.3
作者：
Dang, Chi V.
通讯作者：
Dang, Chi V.
影响因子：
4.2
作者：
Garlick, PJ
通讯作者：
Garlick, PJ
影响因子：
5.7
作者：
Bade, Brett C.;Dela Cruz, Charles S.
通讯作者：
Dela Cruz, Charles S.
细胞外柠檬酸盐促进癌细胞代谢和生长。
影响因子：
5.5
作者：
Haferkamp S;Drexler K;Federlin M;Schlitt HJ;Berneburg M;Adamski J;Gaumann A;Geissler EK;Ganapathy V;Parkinson EK;Mycielska ME
通讯作者：
Mycielska ME